BRIEF published on 09/16/2026 at 07:35, 1 month ago Nicox: NCX 470 data presentation at the 2026 AAOpt Congress Phase 3 Ophthalmology Nicox NCX 470 AAOpt Congress
PRESS RELEASE published on 09/16/2026 at 07:30, 1 month ago Data on Nicox's NCX 470 to be presented at AAOpt Annual Meeting 2026 Nicox presents key data on NCX 470 at AAOpt Annual Meeting 2026, focusing on glaucoma management. Details on clinical trials and future conference participation Clinical Trials Ophthalmology Nicox NCX 470 AAOpt
BRIEF published on 09/11/2026 at 07:35, 1 month 5 days ago Nicox's NCX 470 NDA Accepted for Review in China Ophthalmology NCX 470 Ocumension Therapeutics China Market NDA Review
PRESS RELEASE published on 09/11/2026 at 07:30, 1 month 5 days ago Nicox Announces NCX 470 NDA in China Accepted for Review Nicox announces acceptance of NCX 470 NDA in China by NMPA for review. Regulatory decision expected 12-18 months post-submission. Details on Ocumension and NCX 470 milestones China Nicox NCX 470 Regulatory Decision NMPA
BRIEF published on 09/02/2026 at 07:35, 1 month 14 days ago Nicox Extends Its Cash Flow Horizon Thanks to NCX 470 Ophthalmology NDA Nicox NCX 470 Cash Flow Horizon
BRIEF published on 09/02/2026 at 07:35, 1 month 14 days ago Nicox Announces Financial Stability Extension Financial Update Ophthalmology Nicox NCX 470 Cash Runway
PRESS RELEASE published on 09/02/2026 at 07:30, 1 month 14 days ago Nicox Announces Extension of Cash Runway Nicox extends cash runway with estimated €8.4 million as of 31 August 2026, supporting operations beyond Q1 2028. NCX 470 U.S. NDA approval milestone could fund operations into 2029 Financial Update Ophthalmology Nicox NCX 470 Cash Runway
BRIEF published on 08/27/2026 at 07:35, 1 month 20 days ago Nicox: PDUFA date set for the NCX 470 in April 2027 FDA Glaucoma Nicox NCX 470 PDUFA
PRESS RELEASE published on 08/27/2026 at 07:30, 1 month 20 days ago Nicox Announces April 2027 PDUFA Date for NCX 470 in Glaucoma Nicox announces April 2027 PDUFA date for NCX 470 in Glaucoma. Positive results from Phase 3 trials pave the way for potential FDA approval and commercial launch in H2 2027 FDA Approval Glaucoma Nicox NCX 470 PDUFA Date
BRIEF published on 08/10/2026 at 07:35, 2 months 6 days ago Nicox's NCX 470 NDA Submitted in China Nicox Glaucoma Treatment NCX 470 Ocumension China NDA
Published on 10/16/2026 at 23:35, 3 hours 41 minutes ago Initial Closing of US$3.4 Million Private Placement
Published on 10/16/2026 at 23:30, 3 hours 46 minutes ago NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
Published on 10/16/2026 at 23:00, 4 hours 16 minutes ago Grid Announces Adoption of Advance Notice By-Law and Provides Shareholder Meeting Update
Published on 10/16/2026 at 22:55, 4 hours 21 minutes ago NioCorp Provides Preliminary Unaudited Financial Results for the Three-Month Period Ended September 30, 2026
Published on 10/16/2026 at 15:45, 11 hours 31 minutes ago IBC Advanced Alloys Reports Improved Financial Results for the Year Ended June 2026
Published on 10/16/2026 at 20:08, 7 hours 7 minutes ago EQS-Adhoc: Rath AG // Rath Group reaches agreement with its key financial creditors on the terms of a transformation agreement and launches a transformation programme
Published on 10/16/2026 at 19:20, 7 hours 55 minutes ago Arity to Acquire INRIX, Advancing a Connected Vision for the Future of Transportation
Published on 10/16/2026 at 19:05, 8 hours 10 minutes ago Paris Court Ruling on Discontinued Feature Will Have Minimal Impact on Angelalign Customers
Published on 10/16/2026 at 18:18, 8 hours 57 minutes ago Issue Price of Placing and WRAP Retail Offer
Published on 10/16/2026 at 18:13, 9 hours 2 minutes ago EQS-Adhoc: DHL AG: DHL AG raises full-year 2026 earnings guidance
Published on 10/16/2026 at 18:48, 8 hours 27 minutes ago Disclosure of transactions in own shares from October 12 to October 16, 2026
Published on 10/15/2026 at 18:50, 1 day 8 hours ago September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026
